The Newsletter for the Hospital Practice Seminar!

Providing Your Weekly DOSE  of Speaker and Program Highlights 

Volume 3 • April 19, 2019

Speaker Spotlight

Alex Varkey, Pharm D, MS, FAPhA

Alex C. Varkey, PharmD, MS, FAPhA is the Director of Pharmacy at Houston Methodist Hospital, a 924-bed nonprofit academic teaching hospital in Houston, TX.  Alex received his Doctor of Pharmacy from the University of Houston in 2005.  He then completed a 2-year administrative residency at Nationwide Children’s Hospital in Columbus, OH while completing his Master of Science in Health-System Pharmacy Admin. at The Ohio State University in 2007.Alex has prioritized professional involvement since he was a student, serving as national president of the American Pharmacists Association (APhA) Academy of Student Pharmacists and voting member of the APhA Board of Trustees in 2004-05.  Upon graduating, Varkey remained active with APhA, serving in elected positions in both APhA-APRS and APhA-APPM.  Alex was recently appointed to serve on APhA’s Board of Trustees in January 2018, with the term ending March 2019.  Alex has served in other organizations such as the American Society of Health-System Pharmacists (ASHP), and the Texas Society of Health-System Pharmacists (TSHP) through various appointed positions.  Varkey is an accomplished writer and public speaker, having authored and co-authored several articles in national publications and has served as a keynote speaker at local and national meetings.Varkey is passionate about educating pharmacy learners, having developed a two-year health-system pharmacy administration residency, and a longitudinal pharmacy internship program throughout his tenure at Houston Methodist Hospital.  For his efforts, he has won several awards, including Alumnus Pharmacist of the Year from the University of Houston College of Pharmacy in 2018, the Gulf Coast Society of Health-System Pharmacists Outstanding Pharmacist Award in 2014, and the Outstanding Hospital Preceptor for the Houston/Galveston Region from the University of Texas College of Pharmacy in 2011.

Practice Impact:

Dr. Varkey will present on, Leadership in Pharmacy.  This important session will discuss the challenges hospital pharmacist’s leaders face in the constantly changing healthcare environment. He will describe skills, strengths, and other considerations that help you lead a hospital pharmacy department.   Dr. Varkey will examine formal leadership roles in the healthcare system and how preceptors impact the ability to lead residents, interns, and the pharmacy profession. This course is approved for Preceptor Credit.

A Dose of Antibiotics…

HIV Clinical Pearls for the Inpatient Hospital Pharmacist

Rates of hospitalizations for those receiving antiretroviral therapy (ART) continue to increase with the rising prevalence of HIV-infected patients across the country.  Medication errors are common across the continuum of care in these patients due to the complexity of ART regimens.  This session will present the basics of HIV management and updated recommendations for the prevention of opportunistic infections, as well as strategies to avoid pitfalls of drug-drug interactions and other errors in ART reconciliation during transitions of care.

Dusten Rose, PharmD, BCIDP, BCPS, AAHIVP
Infectious Disease Clinical Pharmacist, Dell Seton Medical Center


Volume 2 • April 19, 2019

Speaker Spotlight

Rebecca Moote, Pharm.D., M.Sc, BCPS. Dr. Moote attended the University of Texas at Austin and received her Doctor of Pharmacy in 2007. She completed her Master of Science in Pharmacy and Advanced Practice Pharmacotherapy Specialty Residency at the University of Texas Health Science Center in San Antonio, Texas in 2009.  Dr. Moote has been teaching for 11 years. She began her academic career in 2007 as a Clinical Instructor of Pharmacy at the University of Texas College of Pharmacy in San Antonio, Texas. She received her first full-time teaching appointment at Regis University School of Pharmacy as an Assistant Professor in 2009 and is now a Clinical Associate Professor at The University of Texas College of Pharmacy. Dr. Moote maintains an active practice in the area of internal medicine. She is a board certified, clinical pharmacy specialist at University Hospital in San Antonio, Texas and she precepts pharmacy students and residents throughout the year. She also has several scholarly interests such as anticoagulation, pulmonary arterial hypertension, and nephrology.  Dr. Moote was recognized for teaching excellence by pharmacy students as Teacher of the Year in 2015 and 2018.

Practice Impact

Dr. Rebecca Moote will discuss, Diuretic Strategies in Acute Decompensated Heart Failure and Kidney Disease.  This session will concentrate on the role of diuretics in the treatment of heart failure and chronic kidney disease as well as identifying common mistakes made in pharmacotherapy decisions with diuretics. As well as reviewing applying pharmacotherapy principals to a patient case.

A Dose of Antibiotics…

Rapid Diagnostics and Implications for Antimicrobial Stewardship

Advancements in microbiology continue to bring incredible technologies that allow clinicians to rapidly identify etiologic pathogens causing infection. It is imperative that hospitals recognize and understand how to use such powerful technologies to their fullest potential.  This presentation will review various technologies currently used for rapid diagnostics in the hospital setting and challenges in implementing such technology.

Gerard Gawrys, Pharm.D., BCIDP, BCPS
Infectious Disease Pharmacist, Methodist Hospital, San Antonio


Volume 1 • April 12, 2019

Speaker Spotlight

The Keynote Speaker for the 2019 HPS will be Craig D. Cox, PharmD, FCCP, BCPS, who is currently an Associate Professor of Pharmacy Practice and Vice Chair of Experiential Programs at Texas Tech University Health Sciences Center School of Pharmacy in Lubbock, Texas.  Dr. Cox is a charismatic speaker who engages his audience with enlightening learning activities that ultimately prove to be life-changing for many attendees.  Dr. Cox has provided numerous preceptor continuing education programs at the local, state, and national level,  and now he’s sharing his insight with HPS attendees!

and through leadership positions with the American Association of Colleges of Pharmacy (AACP), Dr. Cox has led important initiatives in experiential education across the country.  His current research initiatives are focused on preceptor training/development and quality assurance as it relates to experiential education.  Learning with Dr. Cox at HPS will offer pharmacists a great opportunity to receive preceptor training from one of the most experienced and best educators on this topic.  Dr. Cox is currently an Associate Professor of Pharmacy Practice and Vice Chair of Experiential Programs at Texas Tech University Health Sciences Center School of Pharmacy in Lubbock, Texas.

Practice Impact

Dr. Craig Cox will discuss, Good Work-Life Balance with a Focus on Precepting.  This session not only examines the importance of a healthy work-life balance, but it also identifies key strategies for maintaining a balanced life.  With pharmacists facing the reality of burnout and fatigue on a daily basis, it can be a real struggle to pass along a positive outlook while precepting or supervising other pharmacy team members.  Experience how it’s attainable with tools and resources from Dr. Craig Cox. 

Some pharmacists avoid taking on the ‘burden’ of a preceptor role altogether, often due to work-life imbalance.  With the tools and resources that Dr. Cox will share with pharmacist attendees, achieving a healthy work/life balance becomes attainable and personal and professional benefits will follow suit.

A Dose of Antibiotics…

New Antibacterial Agents 2018 and Beyond

After nearly four decades of very few approvals for new antibiotics, we have started to see some traction regarding the development of new products with novel mechanisms of action.  This session will give learners a closer look at each of the antibiotics to have recently entered the market, and their potential place in therapy, as well as the antibiotics in phase 3 development that may be available in the coming year.